drugset / Trial / NCT06860490
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2027-03-10
- Completion
- 2028-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |